On Tuesday, New York Attorney General Eric Schneiderman announced that his office is investigating Mylan Pharmaceuticals Inc, the maker of EpiPen, for potentially using anticompetitive terms in contracts it had with many school systems. Those terms allowed schools to receive Mylan’s EpiPens for free or at discounted prices—as long as they didn’t buy any competitors' products for a year.

The terms may have helped Mylan hike the price of the life-saving medical devices without facing stiff competition from similar epinephrine-injecting products, such as Adrenaclick. Since 2007, the year Mylan acquired EpiPen, the company has raised the price of the pens by more than 400 percent, pushing the list price above $600 (~£446) and drawing sharp public and political criticism.

“No child’s life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker’s anti-competitive practices,” Schneiderman said in a news release. “If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable.”

As STAT reported late last month, more than 65,000 schools across the country participate in Mylan’s “EpiPen4Schools” program, which started in 2012. Many states require that schools have a supply of such devices, which quickly reverse fatal allergic reactions. Mylan’s program offered EpiPens to schools for free or at a discounted rate, which in 2015 was a little more than $100. But schools could participate only if they agreed not to buy any epinephrine auto-injectors from competitors in the following 12 months.

A Mylan spokesperson told STAT that the program no longer includes that requirement, but the company wouldn’t say how recently the term was dropped.

As the public and politicians have become aware of Mylan’s price-hiking ways, the company and its CEO, Heather Bresch, have faced intense scrutiny. Bresch, one of the pharmaceutical industry’s top paid executives who received more than $18 million in compensation last year, said she was “frustrated” by the price increase and shifted blame to the country’s complicated and troubled healthcare system. Mylan now offers a slightly cheaper generic and has expanded its patient assistance programs.

Still, the public and political pressure hasn’t eased. In addition to today’s announcement from New York’s Attorney General, two senators— Richard Blumenthal (D-Conn.) and Amy Klobuchar (D-Minn.)—called on the Federal Trade Commission to investigate if Mylan “deliberately engaged in exclusionary practices to hinder its competitors and maintain its monopoly position in the market.”